Instrument Inactif

Autres langues Getinge AB Other OTC

Actions

GNGBY

US37427X1046

Equipement, fournitures et distribution médicale

Autres langues

17/07	Getinge : Strong Q2 26: Relief rally in full swing
17/07	Getinge AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
17/07	Getinge beats estimates helped by tariff refund, cost controls
17/07	Medical gear maker Getinge Q2 core profit beats estimates
17/07	Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow
16/07	MedTech facing a three-front squeeze
14/07	Getinge – Consensus estimates Q2 2026
03/07	Getinge Receives $36 Million Tariff Refund
03/07	Getinge receives refund of tariffs paid under IEEPA
03/07	Getinge invites fund managers, analysts, and media to Q2 Report 2026 conference call
02/06	Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting
02/06	Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting System
29/05	Ceo buys sek 4.7 million of Getinge shares
28/05	Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in U.S.
28/05	Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.
22/04	Getinge : ACT stumbles, but the thesis holds
21/04	Getinge AB Reports Earnings Results for the First Quarter Ended March 31, 2026
21/04	Resolutions at Getinge's Annual General Meeting April 21, 2026
21/04	Getinge AB Approves Dividend, Payable from April 28, 2026
21/04	Getinge AB Announces Board Elections
21/04	Global markets live: GM, ServiceNow, Uber, Apple, Tesla…
21/04	Getinge lags profit estimates as uncertainty curbs investments in medical equipment
21/04	Getinge : Presentation Q1 2026
21/04	Getinge : Q1 Report 2026
21/04	Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone